US-based Spectrum Pharmaceuticals has launched a digital marketing campaign for its colorectal cancer drug Fusilev (levoleucovorin).
Featuring a new website, healthcare professional (HCP)educational tools, and live peer-to-peer educational programmes, the campaign will be aimed at oncologists, nurses, office practice managers and pharmacists.
“Strong commercial support for Fusilev has been rewarded by increased market penetration and sustained customer loyalty,” said Rajesh Shrotriya, chairman, chief executive officer, and president of Spectrum Pharmaceuticals.
“We believe this campaign will continue to raise awareness of the Fusilev brand as well as grow the folate analog market.”